Kailera Therapeutics, Inc. (KLRA) News
Follow Kailera Therapeutics, Inc. (KLRA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Kailera Therapeutics KLRA Phase 1 Data: Tri-Agonist Shows Up To 16% Weight Loss
Kailera Therapeutics reported Phase 1 data for its tri-agonist, showing up to 16.0% mean weight loss at 12 mg over 12 weeks, with safety consistent with GLP-1s.
EQUITY | Oct 01, 2026, 10:48 AM UTC
L
Kailera Therapeutics, Inc. (KLRA) Completes Enrollment in Three Phase 3 Obesity Trials
Kailera completed enrollment in all three KaiNETIC global Phase 3 trials of ribupatide injection for obesity/overweight. Topline data from KaiNETIC-1, -2, and -3 are expected in mid-2028.Material DetailsContext by AI Ana
NEWS | Sep 30, 2026, 11:09 AM UTC
L
Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection
Kailera Therapeutics Inc NASDAQ:KLRA
NEWS | Sep 30, 2026, 11:02 AM UTC
L
KLRA - Kailera Therapeutics to Participate in September Investor Conferences
KLRA - Kailera Therapeutics to Participate in September Investor Conferences
NEWS | Sep 16, 2026, 11:00 AM UTC
L
KLRA Reports Q2 2026 Financial Results
KLRA reports second quarter 2026 financial results and provides business updates
EARNINGS | Aug 12, 2026, 08:06 PM UTC
L
Why Is Kailera Therapeutics Stock Falling Tuesday?
Kailera Therapeutics Inc. (NASDAQ: KLRA ) stock fell about 9% on Tuesday after the company reported positive topline results from two Phase 3 trials of its oral GLP-1 drug candidate HRS-7535/KAI-7535 in China. Investors
RATES | Jul 07, 2026, 04:45 PM UTC